Cancer therapeutics and computational biology by Immuneering
Andrew Gengos joins Immuneering as new chief financial officer
Immuneering has named Andrew Gengos as its new chief financial officer, signaling a strategic move for the company as it advances its pipeline. Gengos, who previously served at Terns ...
Immuneering draws attention as Mizuho analyst spotlights IMRX pancreatic cancer data at ASCO26
Immuneering has come into focus following remarks by Graig Suvannavejh, biotech analyst at Mizuho Securities, in a recent CNBC interview. Suvannavejh drew attention to the latest clinical trial ...
Immuneering achieves over twofold improvement in first-line pancreatic cancer survival in Phase 2a topline data
Immuneering announced topline results from its Phase 2a clinical trial testing atebimetinib combined with mGnP in 55 patients with first-line pancreatic cancer. The treatment achieved a median ...
Immuneering backs National Cancer Research Month awareness effort
Immuneering is participating in National Cancer Research Month, aligning with the American Association for Cancer Research (AACR), cancer centers, institutions, researchers, physicians, patients, ...
Immuneering rallies teams across regions to boost support for pancreatic cancer efforts
Immuneering employees gathered last weekend in Boston, New Jersey and San Diego to participate in the PanCAN PurpleStride event supporting pancreatic cancer awareness. The company highlighted ...
Immuneering unveils Deep Cyclic Inhibitor atebimetinib for first line pancreatic cancer at AACR meeting
Immuneering has presented a poster at the AACR 2026 Annual Meeting that introduces its Deep Cyclic Inhibitor compound, atebimetinib, as a prospective advance for first line pancreatic cancer ...
Immuneering details advances in pancreatic cancer treatment research
Immuneering CEO Ben Zeskind presented the company unique approach to developing therapies aimed at improving outcomes for cancer patients during a recent conversation on the BrewMarkets podcast. ...
Immuneering unveils Deep Cyclic Inhibitor approach targeting reduced toxicity in cancer therapy
Immuneering has released a new video explaining its Deep Cyclic Inhibitors, a technology developed to minimize cumulative toxicities for cancer patients. The treatment approach is intended to ...
Immuneering executive to hold 1x1 partner sessions at BioEurope Spring
Immuneering announced that Chief Business Officer Harold E B Brakewood will attend the BioEurope Spring conference next week. Brakewood is scheduled to participate in one-on-one partnering ...
Immuneering signals fiscal strategy with atebimetinib trial progress
Immuneering is preparing for the upcoming JPM2026 conference in San Francisco, which is scheduled to occur just one week from now. The biotechnology company is focusing its efforts on promoting ...
Immuneering drives cancer patient survival goals for 2026
Biotechnology firm Immuneering reflects on its achievements throughout 2025 as it makes strides toward its mission of extending the lives of cancer patients beyond their disease. The company ...
Immuneering accelerates pancreatic cancer treatment trials with promising Phase 2a outcomes
Immuneering has taken significant strides in the battle against pancreatic cancer by advancing its Phase 2a trial, which involves the use of atebimetinib in combination with chemotherapy. Recent ...
Immuneering plans Phase 3 development at JPM 2026
Immuneering has announced strategic plans to advance to Phase 3 development of its clinical candidate, atebimetinib. This was shared during their participation at the 44th Annual JPMorgan ...
Immuneering CEO accelerates tumor treatment pipeline at BIO Europe
Immuneering's Chief Business Officer, E.B. Brakewood, actively advanced the company's strategic goals at BIO Europe in Vienna last week. Brakewood provided a company update and engaged in ...
Immuneering drives pancreas disease research at APA Annual Meeting
Immuneering's Chief Scientific Officer is attending the APA Annual Meeting, showcasing their dedication to advancing pancreas disease research. The APA Annual Meeting is a prestigious gathering ...
Immuneering aims to connect with biotech leaders at 2025 Galien Forum
Immuneering, a biotechnology company, is enthusiastic about its participation in the 2025 Galien Forum USA in New York City on October 30. The event promises to be a significant venue for ...
